These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 21742481)
21. An examination of the validity of the standardized field sobriety test in detecting drug impairment using data from the Drug Evaluation and Classification program. Porath-Waller AJ; Beirness DJ Traffic Inj Prev; 2014; 15(2):125-31. PubMed ID: 24345013 [TBL] [Abstract][Full Text] [Related]
22. The detection of illicit drugs in oral fluid: another potential strategy to reduce illicit drug-related harm. Dyer KR; Wilkinson C Drug Alcohol Rev; 2008 Jan; 27(1):99-107. PubMed ID: 18034388 [TBL] [Abstract][Full Text] [Related]
23. Strategies and outcomes in translating alcohol harm reduction research into practice: the Alcohol Linking Program. Wiggers J; Jauncey M; Considine R; Daly J; Kingsland M; Purss K; Burrows S; Nicholas C; Waites R Drug Alcohol Rev; 2004 Sep; 23(3):355-64. PubMed ID: 15370015 [TBL] [Abstract][Full Text] [Related]
24. Drug detection dogs at Australian outdoor music festivals: Deterrent, detection and iatrogenic effects. Grigg J; Barratt MJ; Lenton S Int J Drug Policy; 2018 Oct; 60():89-95. PubMed ID: 30176423 [TBL] [Abstract][Full Text] [Related]
25. Kronic hysteria: exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm. Bright SJ; Bishop B; Kane R; Marsh A; Barratt MJ Int J Drug Policy; 2013 May; 24(3):231-7. PubMed ID: 23333135 [TBL] [Abstract][Full Text] [Related]
26. Policing, massive street drug testing and poly-substance use chaos in Georgia - a policy case study. Otiashvili D; Tabatadze M; Balanchivadze N; Kirtadze I Subst Abuse Treat Prev Policy; 2016 Jan; 11():4. PubMed ID: 26772817 [TBL] [Abstract][Full Text] [Related]
27. Low-threshold methadone treatment, heroin price, police activity and incidence of heroin use: the Zurich experience. Nordt C; Stohler R Int J Drug Policy; 2009 Nov; 20(6):497-501. PubMed ID: 19349154 [TBL] [Abstract][Full Text] [Related]
28. The transition to harm reduction: understanding the role of non-governmental organisations in Malaysia. Narayanan S; Vicknasingam B; Robson NM Int J Drug Policy; 2011 Jul; 22(4):311-7. PubMed ID: 21300533 [TBL] [Abstract][Full Text] [Related]
29. Drug testing in Australian schools: policy implications and considerations of punitive, deterrence and/or prevention measures. Roche AM; Bywood P; Pidd K; Freeman T; Steenson T Int J Drug Policy; 2009 Nov; 20(6):521-8. PubMed ID: 19447026 [TBL] [Abstract][Full Text] [Related]
30. Understanding policy persistence-The case of police drug detection dog policy in NSW, Australia. Hughes CE; Ritter A; Lancaster K; Hoppe R Int J Drug Policy; 2017 Jun; 44():58-68. PubMed ID: 28460274 [TBL] [Abstract][Full Text] [Related]
31. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications. Moore D; Fraser S Soc Sci Med; 2006 Jun; 62(12):3035-47. PubMed ID: 16413645 [TBL] [Abstract][Full Text] [Related]
32. School, parent, and student perspectives of school drug policies. Evans-Whipp TJ; Bond L; Toumbourou JW; Catalano RF J Sch Health; 2007 Mar; 77(3):138-46; quiz 153-4. PubMed ID: 17302856 [TBL] [Abstract][Full Text] [Related]
33. Drug policy, harm and human rights: a rationalist approach. Stevens A Int J Drug Policy; 2011 May; 22(3):233-8. PubMed ID: 21481578 [TBL] [Abstract][Full Text] [Related]
34. Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Mounteney J; Haugland S Int J Drug Policy; 2009 Mar; 20(2):161-9. PubMed ID: 18032012 [TBL] [Abstract][Full Text] [Related]
35. Economic constraint and modes of consumption of addictive goods. Ben Lakhdar C; Bastianic T Int J Drug Policy; 2011 Sep; 22(5):360-5. PubMed ID: 21514133 [TBL] [Abstract][Full Text] [Related]
36. The Cannabis Infringement Notice scheme in Western Australia: a review of policy, police and judicial perspectives. Sutton A; Hawks D Drug Alcohol Rev; 2005 Jul; 24(4):331-6. PubMed ID: 16234128 [TBL] [Abstract][Full Text] [Related]
37. A cross-national comparison of risk and protective factors for adolescent substance use: the United States and Australia. Beyers JM; Toumbourou JW; Catalano RF; Arthur MW; Hawkins JD J Adolesc Health; 2004 Jul; 35(1):3-16. PubMed ID: 15193569 [TBL] [Abstract][Full Text] [Related]
38. Governing through problems: the formulation of policy on amphetamine-type stimulants (ATS) in Australia. Fraser S; Moore D Int J Drug Policy; 2011 Nov; 22(6):498-506. PubMed ID: 22054738 [TBL] [Abstract][Full Text] [Related]
39. GHB in Sydney, Australia, 2000-2006: a case study of the EDRS as a strategic early warning system. Dunn M; Topp L; Degenhardt L Int J Drug Policy; 2009 Sep; 20(5):413-7. PubMed ID: 19237274 [TBL] [Abstract][Full Text] [Related]
40. Harm reduction is now the mainstream global drug policy. Wodak A Addiction; 2009 Mar; 104(3):343-5; discussion 345-6. PubMed ID: 19207340 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]